NCT05721170

Impact of Beta Blockers on TAVI (BETA-TAVI)

Name: Clinical Trial NCT05721170
Creator: National and Kapodistrian University of Athens
Keywords: Aortic Valve Stenosis, Beta blocker, Phase 4, drug, clinical trial

Impact of Beta-blockers Among Patients Undergoing TAVI: a Randomized Multicenter Trial

National and Kapodistrian University of Athens·Phase 4·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Aortic Valve Stenosis
Drug/Device/Intervention: Beta blocker
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: National and Kapodistrian University of Athens

Timeline & enrollment

Phase: Phase 4
Start date: Mar 01, 2023
End date: Jan 31, 2025
Enrollment: 600 participants

Primary outcome

Permanent pacemaker implantation

Summary

This is a prospective, multicentre, investigator-initiated, randomized clinical trial clinical trial investigating the impact of beta-blockers administration among patients undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.

ICD-10 classifications

Aortic (valve) stenosisAortic (valve) stenosis with insufficiencyCongenital stenosis of aortic valveStenosis of aortaRheumatic aortic stenosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05721170
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05721170 through Pure Global AI's free database. This Phase 4 trial is sponsored by National and Kapodistrian University of Athens and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.